Published in World J Cardiol on April 26, 2011
Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21
A common allele on chromosome 9 associated with coronary heart disease. Science (2007) 20.37
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. TIMI Study Group. N Engl J Med (1985) 7.29
Use of a rapid assay of subforms of creatine kinase-MB to diagnose or rule out acute myocardial infarction. N Engl J Med (1994) 7.17
A genome-wide meta-analysis identifies 22 loci associated with eight hematological parameters in the HaemGen consortium. Nat Genet (2009) 6.31
Identification of a genetic locus for familial atrial fibrillation. N Engl J Med (1997) 4.66
Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. N Engl J Med (2001) 4.46
WD-repeat proteins: structure characteristics, biological function, and their involvement in human diseases. Cell Mol Life Sci (2001) 3.38
Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation (2001) 3.21
Design of the Coronary ARtery DIsease Genome-Wide Replication And Meta-Analysis (CARDIoGRAM) Study: A Genome-wide association meta-analysis involving more than 22 000 cases and 60 000 controls. Circ Cardiovasc Genet (2010) 3.15
Gene dosage of the common variant 9p21 predicts severity of coronary artery disease. J Am Coll Cardiol (2010) 3.07
Functional analysis of the chromosome 9p21.3 coronary artery disease risk locus. Arterioscler Thromb Vasc Biol (2009) 2.79
A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. Heparin-Aspirin Reperfusion Trial (HART) Investigators. N Engl J Med (1990) 2.73
Desmin mutation responsible for idiopathic dilated cardiomyopathy. Circulation (1999) 2.59
Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature (1990) 2.46
Angiotensin-converting enzyme polymorphism in hypertrophic cardiomyopathy and sudden cardiac death. Lancet (1993) 2.38
Diltiazem and reinfarction in patients with non-Q-wave myocardial infarction. Results of a double-blind, randomized, multicenter trial. N Engl J Med (1986) 2.26
Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation (2001) 2.23
Novel proteins with binding specificity for DNA CTG repeats and RNA CUG repeats: implications for myotonic dystrophy. Hum Mol Genet (1996) 2.23
A transgenic rabbit model for human hypertrophic cardiomyopathy. J Clin Invest (1999) 2.19
Isolation and sequence analysis of a full-length cDNA for human M creatine kinase. Biochem Biophys Res Commun (1986) 1.96
Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study. Circulation (1991) 1.96
An improved basis for enzymatic estimation of infarct size. Circulation (1975) 1.77
Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy. Circulation (2004) 1.72
Prognostic implications of novel beta cardiac myosin heavy chain gene mutations that cause familial hypertrophic cardiomyopathy. J Clin Invest (1994) 1.69
Altered phosphorylation and intracellular distribution of a (CUG)n triplet repeat RNA-binding protein in patients with myotonic dystrophy and in myotonin protein kinase knockout mice. Proc Natl Acad Sci U S A (1997) 1.66
Autonomous expression of c-myc in BC3H1 cells partially inhibits but does not prevent myogenic differentiation. Mol Cell Biol (1987) 1.52
Myozenin 2 is a novel gene for human hypertrophic cardiomyopathy. Circ Res (2007) 1.51
Human eHAND, but not dHAND, is down-regulated in cardiomyopathies. J Mol Cell Cardiol (2001) 1.50
Dominant-negative effect of a mutant cardiac troponin T on cardiac structure and function in transgenic mice. J Clin Invest (1998) 1.47
Prevention of cardiac hypertrophy by atorvastatin in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circ Res (2005) 1.34
Localization of a gene responsible for arrhythmogenic right ventricular dysplasia to chromosome 3p23. Circulation (1999) 1.29
Expression of a mutant (Arg92Gln) human cardiac troponin T, known to cause hypertrophic cardiomyopathy, impairs adult cardiac myocyte contractility. Circ Res (1997) 1.22
Intravenous recombinant tissue-type plasminogen activator in patients with acute myocardial infarction: a report from the NHLBI thrombolysis in myocardial infarction trial. Circulation (1986) 1.21
Human and murine dystrophin mRNA transcripts are differentially expressed during skeletal muscle, heart, and brain development. Nucleic Acids Res (1992) 1.19
Current concepts of the pathogenesis and treatment of hypertrophic cardiomyopathy. Circulation (2005) 1.15
The locus of a novel gene responsible for arrhythmogenic right-ventricular dysplasia characterized by early onset and high penetrance maps to chromosome 10p12-p14. Am J Hum Genet (2000) 1.09
Hypertrophic cardiomyopathy caused by a novel alpha-tropomyosin mutation (V95A) is associated with mild cardiac phenotype, abnormal calcium binding to troponin, abnormal myosin cycling, and poor prognosis. Circulation (2001) 1.09
Localization of a gene responsible for familial dilated cardiomyopathy to chromosome 1q32. Circulation (1995) 1.09
Mechanisms of disease: Genetic mechanisms of atrial fibrillation. Nat Clin Pract Cardiovasc Med (2006) 1.08
Quantification of serum creatine phosphokinase isoenzyme activity. Am J Cardiol (1974) 1.05
Expression of a missense mutation in the messenger RNA for beta-myosin heavy chain in myocardial tissue in hypertrophic cardiomyopathy. J Clin Invest (1992) 1.01
Genomic organization and isoform-specific tissue expression of human NAPOR (CUGBP2) as a candidate gene for familial arrhythmogenic right ventricular dysplasia. Genomics (2001) 0.98
N-2-mercaptopropionylglycine improves recovery of myocardial function after reversible regional ischemia. J Am Coll Cardiol (1986) 0.97
Expression and localization of dystrophin in human cardiac Purkinje fibers. Circulation (1992) 0.97
Radioimmunoassay for creatine kinase isoenzymes. Science (1976) 0.94
Personalized medicine: a reality within this decade. J Cardiovasc Transl Res (2008) 0.93
Dissociated expression of c-myc and a fos-related competence gene during cardiac myogenesis. Mol Cell Biol (1986) 0.92
Factors influencing enzymatic estimates of infarct size. Am J Cardiol (1977) 0.92
The transcription factor GATA-2 does not associate with angiographic coronary artery disease in the Ottawa Heart Genomics and Cleveland Clinic GeneBank Studies. Hum Genet (2009) 0.92
Purification and characterization of human mitochondrial creatine kinase. A single enzyme form. J Biol Chem (1983) 0.92
Human cardiac and skeletal muscle spectrins: differential expression and localization. Cell Motil Cytoskeleton (1992) 0.90
Effect of propranolol on myocardial-infarct size in a randomized blinded multicenter trial. N Engl J Med (1984) 0.88
Distinct early signaling events resulting from the expression of the PRKAG2 R302Q mutant of AMPK contribute to increased myocardial glycogen. Circ Cardiovasc Genet (2009) 0.88
Genome-wide association studies of hypertension: have they been fruitful? J Cardiovasc Transl Res (2010) 0.88
Sensitive, rapid assay of subforms of creatine kinase MB in plasma. Clin Chem (1989) 0.87
Isolation of a human chromosome 14-only somatic cell hybrid: analysis using Alu and LINE-based PCR. Genomics (1991) 0.86
Reversible myocardial ischemic injury is not associated with increased creatine kinase activity in plasma. Clin Chem (1997) 0.86
In vitro translation of canine mitochondrial creatine kinase messenger RNA. Biochem Biophys Res Commun (1983) 0.85
Impact of age on clinical outcome and postlytic management strategies in patients treated with intravenous thrombolytic therapy. Results from the TIMI II Study. TIMI II Investigators. Circulation (1994) 0.84
Genome-wide association studies--data generation, storage, interpretation, and bioinformatics. J Cardiovasc Transl Res (2010) 0.83
Purification and characterization of naturally occurring and in vitro induced multiple forms of MM creatine kinase. J Biol Chem (1984) 0.82
Identification and characterization of a novel gene (C4orf5) located on human chromosome 4q with specific expression in cardiac and skeletal muscle. Genomics (2000) 0.81
Improved radioimmunoassay for creatine kinase isoenzymes in plasma. Clin Chem (1981) 0.80
Enzyme kinetics of a highly purified mitochondrial creatine kinase in comparison with cytosolic forms. Mol Cell Biochem (1985) 0.79
The Banbury Conference. Genomics to physiology and beyond: how do we get there? Physiologist (1997) 0.79
Serial Alu sequence transposition interrupting a human B creatine kinase pseudogene. Genomics (1991) 0.79
Electrocardiographic, enzymatic and scintigraphic criteria of acute myocardial infarction as determined from study of 726 patients (A MILIS Study). Am J Cardiol (1985) 0.78
Disparity of reperfusion arrhythmias after reversible myocardial ischemia in open chest and conscious dogs. J Am Coll Cardiol (1986) 0.78
Purification and localization of brain-type creatine kinase in sodium chloride transporting epithelia of the spiny dogfish, Squalus acanthias. J Biol Chem (1992) 0.77
Isolation of a de novo mutant myocardial beta MHC protein in a pedigree with hypertrophic cardiomyopathy. Hum Mol Genet (1994) 0.77
Purification of mitochondrial creatine kinase. Biochemical and immunological characterization. J Biol Chem (1980) 0.76
Molecular biology and atrial fibrillation. Curr Opin Cardiol (1999) 0.76